New research reveals these medications impact everything from heart health to restaurant menus.

Since their introduction 20 years ago, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolu­tionised the treatment of diabetes and obesity. Known for their immunomodulatory and ...

Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.

By reinforcing exercise, health care providers can ensure that GLP-1 therapy leads to weight loss, sustains muscle mass, and ...

The landscape of weight management has evolved dramatically in recent years, with GLP-1 receptor agonists like Semaglutide leading the way in treating obesity. However, a new contender has emerged: ...

USA: Therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs) after heart transplantation was associated with ...

MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...

Researchers have been examining other potential health benefits from GLP-1 agonist medications outside of type 2 diabetes management and weight loss. Recent studies have found that GLP-1 medications ...

GLP-1 receptor agonist use appeared linked to significantly reduced all-cause mortality among people with sickle cell disease ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

Diabetes care is undergoing a major transformation driven by GLP-1 receptor agonists, which have expanded beyond glycemic ...